<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8006933</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4649</journal-id>
<journal-id journal-id-type="nlm-ta">J Dev Behav Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">J Dev Behav Pediatr</journal-id>
<journal-title-group>
<journal-title>Journal of developmental and behavioral pediatrics : JDBP</journal-title>
</journal-title-group>
<issn pub-type="ppub">0196-206X</issn>
<issn pub-type="epub">1536-7312</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27096572</article-id>
<article-id pub-id-type="pmc">4907372</article-id>
<article-id pub-id-type="doi">10.1097/DBP.0000000000000299</article-id>
<article-id pub-id-type="manuscript">NIHMS762035</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Creatine Transporter Deficiency: Screening of Males with Neurodevelopmental Disorders and Neurocognitive Characterization of a Case</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Thurm</surname>
<given-names>Audrey</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Himelstein</surname>
<given-names>Daniel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>D'Souza</surname>
<given-names>Precilla</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rennert</surname>
<given-names>Owen</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Susanqi</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olatunji</surname>
<given-names>Damilola</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Longo</surname>
<given-names>Nicola</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pasquali</surname>
<given-names>Marzia</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Swedo</surname>
<given-names>Susan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salomons</surname>
<given-names>Gajja S</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carrillo</surname>
<given-names>Nuria</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Pediatrics and Developmental Neuroscience Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA</aff>
<aff id="A2"><label>2</label>Therapeutics for Rare and Neglected Diseases, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD 20892, USA</aff>
<aff id="A3"><label>3</label>Division of Intramural Research, <italic>Eunice Kennedy Shriver</italic> National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA</aff>
<aff id="A4"><label>4</label>Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA</aff>
<aff id="A5"><label>5</label>Associated Regional and University Pathologists (ARUP) Laboratories, Salt Lake City, Utah, USA</aff>
<aff id="A6"><label>6</label>Department of Pathology, University of Utah, Salt Lake City, Utah, USA</aff>
<aff id="A7"><label>7</label>Department of Clinical Chemistry, Metabolic Unit, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands</aff>
<author-notes>
<corresp id="cor1"><label>*</label>Corresponding author: Audrey Thurm, 10 Center Drive, Rm 1C250, MSC 1255, Bethesda, MD 20892, Office: 301-496-5323, Fax: 301-402-8497, <email>athurm@mail.nih.gov</email></corresp>
<fn fn-type="conflict" id="FN1">
<p id="P23">
<bold>CONFLICTS OF INTEREST</bold>
</p>
<p id="P24">We report no conflicts of interest from any of the authors.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>9</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2017</year>
</pub-date>
<volume>37</volume>
<issue>4</issue>
<fpage>322</fpage>
<lpage>326</lpage>
<!--elocation-id from pubmed: 10.1097/DBP.0000000000000299-->
<abstract>
<sec id="S1">
<title>Objective</title>
<p id="P1">Creatine Transporter Deficiency (CTD) is an X-linked, neurometabolic disorder associated with intellectual disability that is characterized by brain creatine deficiency and caused by mutations in <italic>SLC6A8</italic>, the creatine transporter 1 protein gene. CTD is identified by elevated urine creatine/creatinine ratio or reduced creatine peak on brain magnetic resonance spectroscopy (MRS); the diagnosis is confirmed by decreased creatine uptake in cultured fibroblasts, and/or identification of a mutation in the <italic>SLC6A8</italic> gene. Prevalence studies suggest this disorder may be underdiagnosed. We sought to identify cases from a well-characterized cohort of children diagnosed with neurodevelopmental disorders.</p>
</sec>
<sec id="S2">
<title>Method</title>
<p id="P2">Urine screening for CTD was performed on a cohort of 46 males with autism spectrum disorder (ASD) and 9 males with a history of non-ASD developmental delay classified with intellectual disability.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">We identified one patient with CTD in the cohort based on abnormal urine creatine/creatinine, and confirmed the diagnosis by the identification of a novel frameshift mutation in the <italic>SLC6A8</italic> gene. This patient presented without ASD but with intellectual disability, and was characterized by a non-specific phenotype of early language and developmental delay that persisted into moderate-to-severe intellectual disability, consistent with previous descriptions of CTD.</p>
</sec>
<sec id="S4">
<title>Conclusion</title>
<p id="P4">Identification of patients with CTD is possible by measuring urine creatine and creatinine levels and the current case adds to the growing literature of neurocognitive deficits associated with the disorder affecting cognition, language and behavior in childhood.</p>
</sec>
</abstract>
<kwd-group>
<kwd>autism</kwd>
<kwd>creatine transporter deficiency</kwd>
<kwd>developmental disability</kwd>
<kwd>genetic disease</kwd>
<kwd>X-linked</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>